Cargando…

Association of PD-1/PD-L1 expression and Epstein-–Barr virus infection in patients with invasive breast cancer

PURPOSE: Causative factors of breast cancer include infections, such as Epstein–Barr virus (EBV) infection. The aim of this study was to analyze the clinicopathological features of EBV-positive (IBC) and determine if EBV affects programmed cell death receptor 1 (PD-1)/PD ligand 1 (PD-L1) expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wei-tong, Zhu, Gui-lu, Xu, Wu-qin, Zhang, Wei, Wang, Hui-zhen, Wang, Ya-bing, Li, Yong-xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287995/ https://www.ncbi.nlm.nih.gov/pubmed/35842661 http://dx.doi.org/10.1186/s13000-022-01234-3

Ejemplares similares

Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
por: Derks, Sarah, et al.
Publicado: (2016)

Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma
por: Kase, Kina, et al.
Publicado: (2021)

PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis
por: Grywalska, Ewelina, et al.
Publicado: (2020)

Multi-layered control of PD-L1 expression in Epstein-Barr virus-associated gastric cancer
por: Miliotis, Christos N., et al.
Publicado: (2020)

Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1
por: Ge, Junshang, et al.
Publicado: (2021)

Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein–Barr virus-associated gastric cancer
por: Seo, An Na, et al.
Publicado: (2017)

Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers
por: Sun, Qi, et al.
Publicado: (2022)

Genetic landscape and PD-L1 expression in Epstein–Barr virus-associated gastric cancer according to the histological pattern
por: Park, Ji Hyun, et al.
Publicado: (2023)

Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies
por: Xu, Miao, et al.
Publicado: (2019)

Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy
por: Liu, Yu-Jen, et al.
Publicado: (2018)

Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein–Barr Virus-associated gastric carcinoma
por: Nakayama, Atsuhito, et al.
Publicado: (2019)

Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas
por: Choi, Euno, et al.
Publicado: (2020)

Primary pulmonary lymphoepithelioma-like carcinoma with positive expression of Epstein-Barr virus and PD-L1: A case report
por: Sasaki, Akihiro, et al.
Publicado: (2021)

Analysis of Epstein–Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region
por: Dias, Josiane M., et al.
Publicado: (2022)

Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer
por: Zhang, Li, et al.
Publicado: (2021)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
por: Shi, Wei, et al.
Publicado: (2023)

Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma
por: Li, Xiaoyu, et al.
Publicado: (2022)

P35.20 Genomic Profiling and PD-L1 Expression Association Analysis in Epstein-Barr Virus (EBV)-infected Lung Cancer Patients
por: Yang, X., et al.
Publicado: (2021)

Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer
por: Yang, Na, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

The Methylation Status and Expression of Epstein-Barr Virus Early Genes BARF1 and BHRF1 in Epstein-Barr Virus-Associated Gastric Carcinomas
por: Li, Jing, et al.
Publicado: (2017)

PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro
por: Quan, Lina, et al.
Publicado: (2015)

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
por: Yao, Ji‐Jin, et al.
Publicado: (2017)

PD-L1 Expression Associated with Epstein—Barr Virus Status and Patients’ Survival in a Large Cohort of Gastric Cancer Patients in Northern Brazil
por: de Fátima Aquino Moreira-Nunes, Caroline, et al.
Publicado: (2021)

The Clinical, Pathological, and Prognostic Value of High PD-1 Expression and the Presence of Epstein–Barr Virus Reactivation in Patients with Laryngeal Cancer
por: Klatka, Janusz, et al.
Publicado: (2022)

Massive pericardial effusion due to chronic active Epstein–Barr virus infection successfully treated with PD-1 blockade: A case report
por: Pi, Yubo, et al.
Publicado: (2022)

Successful Treatment of Relapsed Epstein–Barr Virus-Associated Hemophagocytic Lymphohistiocytosis After Allo-HSCT with PD-1 Blockade: A Case Report
por: Pi, Yubo, et al.
Publicado: (2022)

Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer
por: Pan, Yan, et al.
Publicado: (2022)

MCAF1 and Rta-Activated BZLF1 Transcription in Epstein-Barr Virus
por: Lin, Ting-Yu, et al.
Publicado: (2014)

PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations
por: Sun, Xin, et al.
Publicado: (2018)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Wang, Miao, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
por: Qiao, Xin-wei, et al.
Publicado: (2020)

Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade
por: Han, Si-Chong, et al.
Publicado: (2023)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review
por: Liao, Chun-Xu, et al.
Publicado: (2023)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Potential Cellular Functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus
por: Smith, Danielle Westhoff, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jg1hinfd4pvb7hglt0v6ffpe8r